HØRSHOLM, Denmark – 12 August, 2021
Recently, the first healthy volunteer was dosed with GUB002496 in a clinical phase 1 trial.
GUB002496 is a drug candidate aiming for weight reduction.
The advancement of the first of three collaboration projects between Boehringer Ingelheim and Gubra to the clinic marks the achievement of another key milestone.
From this collaboration Gubra may receive up to € 250 million in combined upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales.
Since 2017, Gubra has signed three collaboration and license agreements with Boehringer Ingelheim for the development of novel peptide compounds to treat obesity. The lead candidate from the first of these collaborations, GUB002496, recently advanced into clinical development with the initiation of a clinical phase 1 trial in healthy volunteers. It is a novel peptide with an attractive pharmaceutical profile, which is able to regulate food intake and body weight in pre-clinical models.
This initiation of clinical development triggers another milestone payment. Gubra may receive up to € 250 million in combined upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales from this collaboration.
Compounds that can regulate food intake The aim of the joint research and development program, signed September 2017, is to identify novel peptidic compounds which can regulate food intake.
CEO of Gubra Henrik Blou says:
“It is a huge pleasure to see this project continue into the clinic. Over the years, Gubra has built strong peptide capabilities, lately demonstrated by the development of our new proprietary peptide platform, streaMLine. Our specialization and dedication enable us to play a key role in peptide drug discovery projects together with strong partners. I expect to see more of our peptides entering the clinic in the years to come, both within obesity and a range of other indications.”
Obesity – a rising global health problem, hard to ignore The global prevalence of obesity (BMI ≥30 kg/m2) has increased dramatically over the last decade and nearly tripled between 1975 and 2016 affecting around 650 million adults worldwide today. Current treatment options have limited efficacy in terms of weight loss or are often associated with adverse events. Consequently, there is an unmet medical need for safe and effective treatments to achieve significant weight loss and increase life expectancy for the growing number of patients living with obesity worldwide.
Sofia Pitt Boserup
Lead Communication Partner
Gubra is a privately held biotech company since 2008, headquartered in Denmark. The company is a science and technology driven company with two primary areas of business: Preclinical contract research services (CRO) and proprietary early target and drug discovery programs. Gubra’s primary focus is within the metabolic space (obesity, diabetes, NASH, CKD, CVD and diabetic complications) adding to this fibrotic disease areas such as IPF and IBD. Gubra specializes in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. High quality, scientific excellence, advanced digitalization, speed and solid teamwork, are key company traits which have established Gubra as a highly professional and competent partner in the market. Learn more at www.gubra.dk
World Health Organization. (2020). “Obesity and overweight.” Retrieved from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
Gubra announces the nomination of a co-invented clinical candidate from first obesity collaboration with Boehringer Ingelheim (June 28, 2019)
Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments (Sep 7, 2017)
The post Drug candidate from obesity collaboration between Gubra and Boehringer Ingelheim enters clinical phase 1 trial appeared first on Gubra.